An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
Public ClinicalTrials.gov record NCT02501629. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, 24-Week Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Reslizumab Subcutaneous Dosing (110 mg Every 4 Weeks) in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to determine the ability of reslizumab administered by subcutaneous injection to produce a corticosteroid-sparing effect in patients with oral corticosteroid (OCS)-dependent asthma and elevated blood eosinophils, without loss of asthma control.
Study identification
- NCT ID
- NCT02501629
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 177 participants
Conditions and interventions
Interventions
- Reslizumab Drug
- Placebo Drug
- Non-Oral Corticosteroid (non-OCS) Asthma Medication Drug
- Oral Corticosteroid (OCS) Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2015 (Actual)
- Primary completion
- Jun 19, 2017 (Actual)
- Completion
- Dec 4, 2017 (Actual)
- Last update posted
- Nov 9, 2021
2015 – 2017
United States locations
- U.S. sites
- 26
- U.S. states
- 13
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 13357 | Bakersfield | California | 93301 | — |
| Teva Investigational Site 13365 | Long Beach | California | 90813 | — |
| Teva Investigational Site 13371 | Clermont | Florida | 73034 | — |
| Teva Investigational Site 13351 | Homestead | Florida | 33030 | — |
| Teva Investigational Site 13342 | Kissimmee | Florida | 34741 | — |
| Teva Investigational Site 13344 | Miami | Florida | 33015 | — |
| Teva Investigational Site 13372 | Miami | Florida | 33133 | — |
| Teva Investigational Site 13354 | Pembroke Pines | Florida | 33029 | — |
| Teva Investigational Site 13343 | Saint Cloud | Florida | 34769 | — |
| Teva Investigational Site 13368 | Sebring | Florida | 33870 | — |
| Teva Investigational Site 13346 | Tampa | Florida | 33607 | — |
| Teva Investigational Site 13367 | Chicago | Illinois | 60612 | — |
| Teva Investigational Site 13363 | Normal | Illinois | 61761 | — |
| Teva Investigational Site 13345 | Michigan City | Indiana | 46360 | — |
| Teva Investigational Site 13348 | Lenexa | Kansas | 66215 | — |
| Teva Investigational Site 13362 | Biloxi | Mississippi | 39531 | — |
| Teva Investigational Site 13350 | St Louis | Missouri | 63106 | — |
| Teva Investigational Site 13352 | St Louis | Missouri | 63143 | — |
| Teva Investigational Site 13356 | New York | New York | 10016-9196 | — |
| Teva Investigational Site 13349 | Cincinnati | Ohio | 45231 | — |
| Teva Investigational Site 13370 | Edmond | Oklahoma | 73034 | — |
| Teva Investigational Site 13347 | Oklahoma City | Oklahoma | 73112 | — |
| Teva Investigational Site 13366 | Charleston | South Carolina | 29414 | — |
| Teva Investigational Site 13377 | Dallas | Texas | 75225 | — |
| Teva Investigational Site 13369 | Houston | Texas | 77099 | — |
| Teva Investigational Site 13358 | Fairfax | Virginia | 22030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 101 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02501629, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02501629 live on ClinicalTrials.gov.